Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Coralie Reger de Moura"'
Autor:
Julie Delyon, Anaïs Vallet, Mélanie Bernard-Cacciarella, Isabelle Kuzniak, Coralie Reger de Moura, Baptiste Louveau, Fanélie Jouenne, Samia Mourah, Céleste Lebbé, Nicolas Dumaz
Publikováno v:
Cancers, Vol 15, Iss 11, p 2888 (2023)
Because BRAF-mutated melanomas are addicted to the Mitogen Activated Protein Kinase (MAPK) pathway they show a high response rate to BRAF and MEK inhibitors. However, the clinical responses to these inhibitors are often short-lived with the rapid ons
Externí odkaz:
https://doaj.org/article/9fa529c6951d44579b7cafcac78fb957
Autor:
Coralie Reger de Moura, Laetitia Vercellino, Fanélie Jouenne, Barouyr Baroudjian, Aurélie Sadoux, Baptiste Louveau, Julie Delyon, Kevin Serror, Lauriane Goldwirt, Pascal Merlet, Fanny Bouquet, Maxime Battistella, Céleste Lebbé, Samia Mourah
Publikováno v:
Translational Oncology, Vol 13, Iss 2, Pp 275-286 (2020)
The development of BRAF and MEK inhibitors (BRAFi/MEKi) has led to major advances in melanoma treatment. However, the emergence of resistance mechanisms limits the benefit duration and a complete response occurs in less than 20% of patients receiving
Externí odkaz:
https://doaj.org/article/3c608e0fc0b044eab9dd9e6fd7ebe3ad
Autor:
Coralie Reger de Moura, Marco Prunotto, Anjum Sohail, Maxime Battistella, Fanelie Jouenne, Daniel Marbach, Celeste Lebbé, Rafael Fridman, Samia Mourah
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Melanoma is a highly malignant skin cancer with high propensity to metastasize and develop drug resistance, making it a difficult cancer to treat. Current therapies targeting BRAF (V600) mutations are initially effective, but eventually tumors overco
Externí odkaz:
https://doaj.org/article/8f5676d279c94009b1fe2c5c4e48898a
Autor:
Coralie Reger de Moura, Alexandra Landras, Farah Khayati, Uwe Maskos, Kamel Maouche, Maxime Battistella, Suzanne Menashi, Céleste Lebbé, Samia Mourah
Publikováno v:
Cancers, Vol 13, Iss 19, p 4859 (2021)
Malignant melanoma is one of the most aggressive skin cancers and is characterized by early lymph node metastasis and the capacity to develop resistance to therapies. Hence, understanding the regulation of lymphangiogenesis through mechanisms contrib
Externí odkaz:
https://doaj.org/article/35022fab91a54a0c89342144998d6071
Autor:
Pauline Tétu, Julie Delyon, Jocelyne André, Coralie Reger de Moura, Malak Sabbah, Ghanem E Ghanem, Maxime Battistella, Samia Mourah, Céleste Lebbé, Nicolas Dumaz
Publikováno v:
Cancers, Vol 12, Iss 5, p 1062 (2020)
KIT is a bona fide oncogene in a subset of melanoma and, ex vivo, KIT inhibitors are very efficient at killing KIT-mutant melanoma cell lines. However, KIT-mutant melanoma tumors tend to show a de novo resistance in most cases and a limited duration
Externí odkaz:
https://doaj.org/article/5bd985c089ae4443aeeec7255d17093a
Autor:
Alexandra Landras, Coralie Reger de Moura, Fanelie Jouenne, Celeste Lebbe, Suzanne Menashi, Samia Mourah
Publikováno v:
Cancers, Vol 11, Iss 11, p 1803 (2019)
Microenvironment plays a crucial role in tumor development and progression. Cancer cells modulate the tumor microenvironment, which also contribute to resistance to therapy. Identifying biomarkers involved in tumorigenesis and cancer progression repr
Externí odkaz:
https://doaj.org/article/c62fe0d34b6442acb2de128271a7af95
Autor:
Baptiste Louveau, Fanelie Jouenne, Coralie Reger de Moura, Aurelie Sadoux, Barouyr Baroudjian, Julie Delyon, Florian Herms, Adele De Masson, Laetitia Da Meda, Maxime Battistella, Nicolas Dumaz, Celeste Lebbe, Samia Mourah
Publikováno v:
Cancers, Vol 11, Iss 8, p 1203 (2019)
In BRAFV600mut metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III
Externí odkaz:
https://doaj.org/article/19a0c4c71b7f463794e13b2a99593c1e
Autor:
Céleste Lebbe, Samia Mourah, Maxime Battistella, Keyvan Rezai, Samuel Huguet, Annick Tibi, Didier Bouton, Paul Vilquin, Zineb Ghrieb, Fanélie Jouenne, Aurélie Sadoux, Coralie Reger de Moura, Caroline Dutriaux, Mona Amini-Adle, Julie Delyon, Barouyr Baroudjian, Marc Pracht, Laetitia Da Meda, Thierry Lesimple, Matthieu Resche-Rigon, Baptiste Louveau
Figure S2. (A) Change in the tumor burden from baseline over time according to RECIST for all the included patients. The tumor burden was measured as the sum of the longest diameters of target lesions. Each line represents a patient. (B) Kaplan-Meier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::272e3c9431d2fe17ad4e23f5c0092460
https://doi.org/10.1158/1078-0432.22480554
https://doi.org/10.1158/1078-0432.22480554
Autor:
Céleste Lebbe, Samia Mourah, Maxime Battistella, Keyvan Rezai, Samuel Huguet, Annick Tibi, Didier Bouton, Paul Vilquin, Zineb Ghrieb, Fanélie Jouenne, Aurélie Sadoux, Coralie Reger de Moura, Caroline Dutriaux, Mona Amini-Adle, Julie Delyon, Barouyr Baroudjian, Marc Pracht, Laetitia Da Meda, Thierry Lesimple, Matthieu Resche-Rigon, Baptiste Louveau
Purpose:In BRAFV600MUT metastatic melanoma, cyclin D–CDK4/6–INK4–Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors. In this phase I–II study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b3af0eef26415c8819e4c5b5543de08
https://doi.org/10.1158/1078-0432.c.6530460
https://doi.org/10.1158/1078-0432.c.6530460
Autor:
Céleste Lebbe, Samia Mourah, Maxime Battistella, Keyvan Rezai, Samuel Huguet, Annick Tibi, Didier Bouton, Paul Vilquin, Zineb Ghrieb, Fanélie Jouenne, Aurélie Sadoux, Coralie Reger de Moura, Caroline Dutriaux, Mona Amini-Adle, Julie Delyon, Barouyr Baroudjian, Marc Pracht, Laetitia Da Meda, Thierry Lesimple, Matthieu Resche-Rigon, Baptiste Louveau
Supplementary Materials and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b0cb79529fe16cf7b7f5ecfa443c579
https://doi.org/10.1158/1078-0432.22480545
https://doi.org/10.1158/1078-0432.22480545